25-hydroxy vitamin D levels in patients with myelofibrosis and potential relationships with disease severity: A case-control study: Vitamin D levels in myelofibrosis patients

Yildiz Ipek

doi:10.28982/josam.7923

Authors

Yildiz Ipek Department of Hematology, Kartal Lutfi Kirdar City Hospital, Istanbul, Turkey https://orcid.org/0000-0003-2952-2286

DOI:

https://doi.org/10.28982/josam.7923

Keywords:

dynamic international prognostic scoring system, myeloproliferative neoplasm, myelofibrosis, prognosis, vitamin D

Abstract

Background/Aim: Although vitamin D deficiency has been associated with cancer and its prognosis, data is unclear regarding associations with myelofibrosis. This study aimed to measure 25-hydroxy vitamin D levels in patients with myelofibrosis and to evaluate its relationship with prognoses.

Methods: This case-control study consisted of 72 patients with myelofibrosis and 75 controls. The Dynamic International Prognostic Scoring System was used to determine prognostic risk groups, and patients were divided into two subgroups: intermediate-1 (low risk) and intermediate-2 (high risk).

Results: The median 25-OHD levels were decreased in the myelofibrosis group more so than in the controls (13.05 vs. 23.0 ng/mL, P<0.001). A cut-off value of ≤ 16.5 ng/mL yielded a sensitivity of 84.72% and a specificity of 80% for the identification of patients with myelofibrosis. This impact was also evident when adjusted for age and sex, showing that patients with low 25-hydroxy vitamin D (≤16.5) had a 23.787-fold higher probability to have myelofibrosis (OR: 23.787, 95% CI: 9.676-58.479, P<0.001). When examined for the two prognostic subgroups, 25-hydroxy vitamin D was found to be significantly lower in the intermediate-2 and high subgroup (P=0.017). For a cut-off value of ≤13.7 ng/mL, 25-hydroxy vitamin D level was able to discriminate patients in the intermediate-2 and high subgroup from those with lower risk (sensitivity: 77.8%, specificity: 55.6%).

Conclusion: A serum 25-hydroxy vitamin D level may serve as a biomarker associated with myelofibrosis diagnosis and prognosis; however, the discriminatory value for prognostic groups was low, indicating the need for larger and longitudinally-designed studies.

Downloads

Download data is not yet available.

References

Tefferi A, Gangat N, Pardanani A, Crispino JD. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 2022;82(5):749-63.

Garmezy B, Schaefer JK, Mercer J, Talpaz M. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Rev. 2021;45:100691.

Mascarenhas J, Gleitz HF, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, et al. Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 2023;37(2):255-64.

Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954-70.

Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. The health effects of vitamin D supplementation: Evidence from human studies. Nat Rev Endocrinol. 2022;18(2):96-110.

Carlberg C, Muñoz A, editors. An update on vitamin D signaling and cancer. Semin Cancer Biol; 2022:79:217-30

Samadi A, Sabuncuoglu S, Samadi M, Isikhan SY, Chirumbolo S, Peana M, et al. A Comprehensive Review on Oxysterols and Related Diseases. Curr Med Chem. 2021;28(1):110-36.

Merchan BB, Morcillo S, Martin-Nunez G, Tinahones FJ, Macias-Gonzalez M. The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences. J Steroid Biochem Mol Biol. 2017;167:203-18.

Liu D, Meng X, Tian Q, Cao W, Fan X, Wu L, et al. Vitamin D and multiple health outcomes: an umbrella review of observational studies, randomized controlled trials, and Mendelian randomization studies. Adv Nutr. 2022;13(4):1044-62.

Pardanani A, Drake MT, Finke C, Lasho TL, Rozell SA, Jimma T, et al. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Am J Hematol. 2011;86(12):1013-6.

Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.

Oken M, Horton D, Davis T, Carbone E. ECoG performance status. Am J Clin Oncol. 1982;5:649-55.

Janoušek J, Pilařová V, Macáková K, Nomura A, Veiga-Matos J, Silva DDD, et al. Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites. Crit Rev Clin Lab Sci. 2022;59(8):517-54.

Arora J, Wang J, Weaver V, Zhang Y, Cantorna MT. Novel insight into the role of the vitamin D receptor in the development and function of the immune system. J Steroid Biochem Mol Biol. 2022;219:106084.

Gabryanczyk A, Klimczak S, Szymczak-Pajor I, Śliwińska A. Is vitamin D deficiency related to increased cancer risk in patients with type 2 diabetes mellitus? Int J Mol Sci. 2021;22(12):6444.

Oztas Y, Yalcinkaya A. Oxidative alterations in sickle cell disease: possible involvement in disease pathogenesis. World J Hematol. 2017;6(3):55-61.

De Martinis M, Allegra A, Sirufo MM, Tonacci A, Pioggia G, Raggiunti M, et al. Vitamin D deficiency, osteoporosis and effect on autoimmune diseases and hematopoiesis: a review. Int J Mol Sci. 2021;22(16):8855.

Acar S, Özkan B. Vitamin D metabolism. In: Özdemir Ö, editor. Vitamin D. London, United Kingdom: IntechOpen; 2021.

Ito Y, Honda A, Kurokawa M. Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: A meta-analysis. Blood Advances. 2022;6(5):1499-511.

Chen P, Cao Y, Duan X, Li J, Zhao W, Wang H. Bioavailable 25 (OH) D level is associated with clinical outcomes of patients with diffuse large B-cell lymphoma: An exploratory study. Clin Nutr. 2021;40(1):157-65.

Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492-8.

Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, et al. Low 25 (OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 2014;120(4):521-9.

Balkan C, Ersoy B, Nese N. Myelofibrosis associated with severe vitamin D deficiency rickets. J Int Med Res. 2005;33(3):356-9.

Venkatnarayan K, Gupta A, Adhikari K. Reversible myelofibrosis due to severe Vitamin D deficiency rickets. Med J Armed Forces India. 2018;74(4):404.

Yetgin S, Özsoylu Ş, Ruacan Ş, Tekinalp G, Sarialiolu F. Vitamin D-deficiency rickets and myelofibrosis. J Pediatr. 1989;114(2):213-7.

Elidrissy A. Myelofibrosis associated, with Rickets, is it hyperparathyroidism the triggering agent or vitamin D and hypocalcemia or hypophosphatemia. Int J Clin Endocrinol Metab. 2016;2(01):019-23.

Stephan J, Galambrun C, Dutour A, Freycon F. Myelofibrosis: an unusual presentation of vitamin D-deficient rickets. Eur J Pediatr. 1999;158(10):828.

Parikh AC, Singhal T, Upadhyay Z. Vitamin-D Deficiency and Myelofibrosis: A Rare but Reversible Association. J Child Sci. 2021;11(01):e18-e9.

Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(9):1033-62.

Torfadottir JE, Aspelund T, Valdimarsdottir UA, Cotch MF, Tryggvadottir L, Harris TB, et al. Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients. Cancer Causes Control. 2019;30(4):333-42.